N4 Pharma Management
Management criteria checks 3/4
N4 Pharma's CEO is Nigel Theobald, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is £82.50K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4.3% of the company’s shares, worth £89.15K. The average tenure of the management team and the board of directors is 5.6 years and 5.6 years respectively.
Key information
Nigel Theobald
Chief executive officer
UK£82.5k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 10.9yrs |
| CEO ownership | 4.3% |
| Management average tenure | 5.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In Growth
Oct 11
Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
Jul 06Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?
Mar 18Here's What We Think About N4 Pharma's (LON:N4P) CEO Pay
Mar 01Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In Growth
Dec 07
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£1m |
| Mar 31 2024 | n/a | n/a | -UK£1m |
| Dec 31 2023 | UK£83k | UK£83k | -UK£1m |
| Sep 30 2023 | n/a | n/a | -UK£1m |
| Jun 30 2023 | n/a | n/a | -UK£925k |
| Mar 31 2023 | n/a | n/a | -UK£977k |
| Dec 31 2022 | UK£78k | UK£78k | -UK£1m |
| Sep 30 2022 | n/a | n/a | -UK£1m |
| Jun 30 2022 | n/a | n/a | -UK£1m |
| Mar 31 2022 | n/a | n/a | -UK£1m |
| Dec 31 2021 | UK£75k | UK£75k | -UK£2m |
| Sep 30 2021 | n/a | n/a | -UK£2m |
| Jun 30 2021 | n/a | n/a | -UK£2m |
| Mar 31 2021 | n/a | n/a | -UK£2m |
| Dec 31 2020 | UK£72k | UK£72k | -UK£1m |
| Sep 30 2020 | n/a | n/a | -UK£1m |
| Jun 30 2020 | n/a | n/a | -UK£863k |
| Mar 31 2020 | n/a | n/a | -UK£869k |
| Dec 31 2019 | UK£70k | UK£70k | -UK£876k |
| Sep 30 2019 | n/a | n/a | -UK£1m |
| Jun 30 2019 | n/a | n/a | -UK£1m |
| Mar 31 2019 | n/a | n/a | -UK£1m |
| Dec 31 2018 | UK£70k | UK£70k | -UK£1m |
Compensation vs Market: Nigel's total compensation ($USD103.36K) is below average for companies of similar size in the UK market ($USD347.06K).
Compensation vs Earnings: Nigel's compensation has increased whilst the company is unprofitable.
CEO
Nigel Theobald (60 yo)
10.9yrs
Tenure
UK£82,500
Compensation
Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Executive Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 10.9yrs | UK£82.50k | 4.3% £ 89.2k | |
| Executive Director & Technical Director | 5.6yrs | UK£51.22k | no data | |
| Executive Director | 4.4yrs | UK£45.72k | 0.036% £ 750.1 | |
| Head of CMC Development | 4.8yrs | no data | no data | |
| Consultant | 5.9yrs | no data | no data |
5.6yrs
Average Tenure
60yo
Average Age
Experienced Management: N4P's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | UK£82.50k | 4.3% £ 89.2k | |
| Executive Director & Technical Director | 7.6yrs | UK£51.22k | no data | |
| Executive Director | no data | UK£45.72k | 0.036% £ 750.1 | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Chairman | 5.6yrs | UK£24.00k | no data |
5.6yrs
Average Tenure
60yo
Average Age
Experienced Board: N4P's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 23:29 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
N4 Pharma Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Emma Ulker | Allenby Capital Limited |